Vision Fund investment portfolio company Tessera Therapeutics's logo

Tessera Therapeutics is pioneering Gene Writing, a new category of genetic medicine.

Leadership
Michael Severino
Fund
SVF2
Status
Private
Sector
Health Tech
Region
Americas